\n\n
A recent report highlights a new safety concern for widely used GLP‑1 medications like Ozempic and Wegovy. Researchers found that users of these popular weight‑loss therapies are experiencing significantly higher incidences of nail detachment, hair loss, and scalp inflammation than the general population. The findings suggest that while GLP‑1 drugs are effective for weight management and diabetes control, clinicians should monitor patients for these dermatologic side effects and counsel them on early signs. Ongoing surveillance and further studies will be needed to determine the underlying mechanisms and whether dosage adjustments or alternative treatments can mitigate the risk. [[1]]